Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey. Show more
Location: 55 Madison Avenue, Morristown, NJ, 07960, United States | Website: https://hepionpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
746.4K
52 Wk Range
$0.04 - $56.00
Previous Close
$0.07
Open
$0.06
Volume
49,244
Day Range
$0.06 - $0.07
Enterprise Value
-1.487M
Cash
4.586M
Avg Qtr Burn
-3.929M
Insider Ownership
0.19%
Institutional Own.
8.95%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
HEPA-CRV431-210 (rencofilstat) Details Non-alcoholic steatohepatitis , Hepatitis B | Phase 2b Update | |
HEPA-CRV431-207 (rencofilstat) Details Hepatitis B, Non-alcoholic steatohepatitis | Failed Discontinued |